Manufactured by Eli Lilly and Company, both Mounjaro and Zepbound contain the ... up to 50% of patients experienced gastrointestinal issues and other adverse effects after taking a 15-mg dose of ...

Eli Lilly is expanding the supply and cutting ... The drug is available in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg per 0.5 mL doses in a single-dose pen. Get a brief on the top business ...

But Lilly and Novo Nordisk continue to welcome ... it remains to be seen if Mounjaro 15 mg would outperform Ozempic 2 mg in a head-to-head trial. However, simply increasing dosage is not always ...

Eli Lilly has lowered the price of its weight-loss drug Zepbound for patients paying out of pocket and introduced two new available vial doses.

Eli Lilly and Company’s LLY shares dipped almost 5% on Monday after rival Novo Nordisk NVO announced disappointing data from ...

Then, in March 2024, shortly after his doctor upped his dosage to 2.5 milligrams (he’d started at 1.5 mg), he woke up ... file a lawsuit against Mounjaro drugmaker Lilly and Company.

Eli Lilly is expanding the supply and cutting the costs of its weight-loss drug Zepbound, broadening access to more patients without insurance. The company launched 7.5 mg and 10 mg vials of ...

Eli Lilly is ... prices of the 2.5 mg and 5 mg vials to $349 and $499 per month, respectively. The company, which has seen a significant boost in profits from Zepbound and Mounjaro – essentially ...

On the other hand, these tailwinds have been negated by the underwhelming numbers observed in LLY's next-gen daily oral candidate, Orforglipron at 24 mg (expected launch by end-2026) with -8.5% in ...

Altimmune's pemvidutide shows promise in treating MASH and obesity, with upcoming Phase 2b results poised to shape its market impact. Read more on ALT stock here.